1061 related articles for article (PubMed ID: 37193982)
21. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
22. Echinocandin resistance among Candida isolates at an academic medical centre 2005-15: analysis of trends and outcomes.
McCarty TP; Lockhart SR; Moser SA; Whiddon J; Zurko J; Pham CD; Pappas PG
J Antimicrob Chemother; 2018 Jun; 73(6):1677-1680. PubMed ID: 29506044
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.
Carvalhaes CG; Rhomberg PR; Pfaller MA; Locke JB; Castanheira M
Mycoses; 2022 Nov; 65(11):1040-1044. PubMed ID: 35778886
[TBL] [Abstract][Full Text] [Related]
24. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
Pfaller MA; Castanheira M; Lockhart SR; Ahlquist AM; Messer SA; Jones RN
J Clin Microbiol; 2012 Apr; 50(4):1199-203. PubMed ID: 22278842
[TBL] [Abstract][Full Text] [Related]
25. Antifungal susceptibility of Candida isolates at one institution.
Katsuragi S; Sata M; Kobayashi Y; Miyoshi T; Yamashita Y; Neki R; Horiuchi C; Yamanaka K; Kamiya C; Iwanaga N; Tanaka H; Ikeda T; Yoshimatsu J
Med Mycol J; 2014; 55(1):E1-7. PubMed ID: 24682093
[TBL] [Abstract][Full Text] [Related]
26. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
[TBL] [Abstract][Full Text] [Related]
27. Antifungal resistance does not necessarily affect Candida glabrata fitness.
Borghi E; Andreoni S; Cirasola D; Ricucci V; Sciota R; Morace G
J Chemother; 2014 Feb; 26(1):32-6. PubMed ID: 24091025
[TBL] [Abstract][Full Text] [Related]
28. Unexpected effects of azole transporter inhibitors on antifungal susceptibility in Candida glabrata and other pathogenic Candida species.
Nagayoshi Y; Miyazaki T; Shimamura S; Nakayama H; Minematsu A; Yamauchi S; Takazono T; Nakamura S; Yanagihara K; Kohno S; Mukae H; Izumikawa K
PLoS One; 2017; 12(7):e0180990. PubMed ID: 28700656
[TBL] [Abstract][Full Text] [Related]
29. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia.
Lindberg E; Hammarström H; Ataollahy N; Kondori N
Sci Rep; 2019 Mar; 9(1):3838. PubMed ID: 30846717
[TBL] [Abstract][Full Text] [Related]
30. Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?
Le A; Farmakiotis D; Tarrand JJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584138
[TBL] [Abstract][Full Text] [Related]
31. Infectious endocarditis caused by Candida glabrata: evidence of in vivo development of echinocandin resistance.
Agnelli C; Guinea J; Valerio M; Escribano P; Bouza E; Muñoz P
Rev Esp Quimioter; 2019 Aug; 32(4):395-397. PubMed ID: 31327188
[No Abstract] [Full Text] [Related]
32. Comparison of Six Antifungal Susceptibilities of 11
Lee H; Choi SH; Oh J; Koo J; Lee HJ; Cho SI; Shin JH; Lee HK; Kim SY; Lee CH; Kim YR; Sohn YH; Kim WJ; Ryu SW; Sung GH; Kim J
Microbiol Spectr; 2022 Apr; 10(2):e0125321. PubMed ID: 35384691
[TBL] [Abstract][Full Text] [Related]
33. Failure of echinocandin therapy in the treatment of Candida glabrata chorioretinitis.
Mousselli HA; Norwood J
Am J Med Sci; 2012 Jan; 343(1):98-100. PubMed ID: 22052412
[TBL] [Abstract][Full Text] [Related]
34. Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC.
Saraya T; Tanabe K; Araki K; Yonetani S; Makino H; Watanabe T; Tsujimoto N; Takata S; Kurai D; Ishii H; Miyazaki Y; Takizawa H; Goto H
J Clin Microbiol; 2014 Jul; 52(7):2709-12. PubMed ID: 24789192
[TBL] [Abstract][Full Text] [Related]
35. Spontaneous Mutational Frequency and
Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
[TBL] [Abstract][Full Text] [Related]
36. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.
Guinea J; Zaragoza Ó; Escribano P; Martín-Mazuelos E; Pemán J; Sánchez-Reus F; Cuenca-Estrella M;
Antimicrob Agents Chemother; 2014; 58(3):1529-37. PubMed ID: 24366741
[TBL] [Abstract][Full Text] [Related]
37. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea.
Jung SI; Shin JH; Song JH; Peck KR; Lee K; Kim MN; Chang HH; Moon CS;
Med Mycol; 2010 Jun; 48(4):669-74. PubMed ID: 20392145
[TBL] [Abstract][Full Text] [Related]
38. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
39. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
40. New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species.
Johnson ME; Katiyar SK; Edlind TD
Antimicrob Agents Chemother; 2011 Aug; 55(8):3774-81. PubMed ID: 21576441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
